PositiveID declared that its recently acquired auxiliary company, MicroFluidic Systems (MFSI), has qualified and submitted a proposal for a government contract. The contract raises the company’s potential government contracts to more than $37 million. PositiveID develops medical technologies for clinical diagnostics, diabetes management and bio-threat monitoring. MFSI produces systems for sample preparation and biological testing.
MFSI has already submitted a few contracts and is in the process of submitting a few others which are due to be awarded in 2011. MFSI has recently submitted a proposal for a cartridge-based radiation dosimeter that utilizes the Dragonfly technology.
MFSI produces automated equipment for a wide variety of applications such as detecting and processing biological samples. MFSI has earned more than $45 million in revenue through government contracts. Most of the contracts were signed by MFSI with the Department of Homeland Security. MFSI has also made proposals to the Department of Defense and Health and Human Services.
The key products offered by MFSI include Dragonfly and Microfluidics-based Bioagent Autonomous Networked Detector (M-BAND) solutions. The Dragonfly solution comprises minute microfluidic cartridges that can be used for biological sample detection and processing and for clinical sample detection and processing.
The M-Band is a pathogen detection device that can serve as an emergency alert mechanism for protection from a biological attack. This detection system offers high-sensitivity and comes equipped with an autonomous bio-aerosol display. It analyzes air samples to detect the presence of viruses, bacteria, and toxins and generates results in less than two hours.